Novel Transdermal Topical Analgesic Formulation May Decrease Treatment Pauses During Microfocused Ultrasound

Topical Cream
Topical Cream
The investigators concluded that fewer treatment pauses due to patient discomfort may translate into time efficiency.

Lidocaine 4% and benzocaine 20% formulations administered through a novel transdermal delivery system perform in a similar fashion to compounded lidocaine 23%/tetracaine 7% (23/7) for lessening discomfort during the administration of microfocused ultrasound with visualization (MFU-V), according to the results of a randomized double-blind split-face study published in the Journal of Drugs in Dermatology.

The investigators sought to compare 2 topical analgesics (lidocaine 4% and benzocaine 20%) formulated with a novel transdermal delivery system with compounded 23/7 for the mitigation of discomfort during MFU-V therapy. At 1 hour prior to MFU-V, a total of 14 female participants received 50 mg intramuscular (IM) meperidine/25 mg IM promethazine/5 mg oral diazepam. At 15 minutes prior to the treatment, 1 side of each participant’s face was treated with 1 application of 4% lidocaine, followed by 1 application of 20% benzocaine. The other side of that same participant’s face was treated with 2 applications of 23/7 in order to maintain blinding.

Numbness was assessed by a blinded evaluator (1=completely numb to 4=not numb) pretreatment. All participants’ pain scores (0=no pain to 10=worst pain) were collected post-treatment. Subjective clinical measures and adverse events were also evaluated.

Mean participant pain scores with 23/7 and lidocaine 4%/benzocaine 20% were 5.6 and 5.7, respectively. Mean numbness scores were also similar (2.5 with 23/7 vs 3.0 with lidocaine 4%/benzocaine 20%). The clinicians rated both products as being “very easy” to apply. With lidocaine 4%/benzocaine 20%, overall, 7.1% of participants required no pauses during treatment compared with 14.3% who required pauses with 23/7. More participants required 4+ pauses with 23/7 than with lidocaine 4%/benzocaine 20% (21.4% vs 7.1%, respectively).

Related Articles

Lidocaine 4%/benzocaine/20% was preferred by 78.5% of participants, with 35.7% rating lidocaine 4%/benzocaine 20% as “very effective” vs 7.1% for 23/7. No adverse events were reported.

The investigators concluded that fewer treatment pauses due to patient discomfort in participants using the lidocaine 4%/benzocaine 20% formulation may translate into time efficiency.


Palm MD, Misell LM. Topical transdermally delivered lidocaine and benzocaine compared to compounded lidocaine/tetracaine during microfocused ultrasound with visualization treatment. J Drugs Dermatol. 2018;17(7):729-734.